Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease

Letter: Early real‐world evidence from the United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease—Authors' reply

Published:2024-05-23 Issue:1 Volume:60 Page:103-104
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Yiu Tsz Hong¹^ORCID,Ko Yanna²³,Pudipeddi Aviv³,Natale Patrizia¹⁴⁵,Leong Rupert W.³

Affiliation:

1. School of Public Health University of Sydney Sydney New South Wales Australia

2. School of Medicine Western Sydney University Sydney New South Wales Australia

3. Gastrointestinal and Liver Services Research Unit Concord Repatriation General Hospital Sydney New South Wales Australia

4. Department of Precision and Regenerative Medicine and Ionian Area (DIMEPRE‐J) University of Bari Aldo Moro Bari Italy

5. Nephrology, Dialysis and Transplantation Unit, Department of Medical and Surgical Sciences University of Foggia Foggia Italy

Abstract

LINKED CONTENTThis article is linked to Yiu et al papers. To view these articles, visit https://doi.org/10.1111/apt.18006 and https://doi.org/10.1111/apt.18049

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.18057

Reference6 articles.

1. Letter: early real‐world evidence from The United Arab Emirates of the persistence, effectiveness and safety of risankizumab for the treatment of Crohn's disease;Alahmad M;Aliment Pharmacol Ther,2024

2. Meta‐analysis: Persistence of advanced therapies in the treatment of inflammatory bowel disease

3. Risankizumab effectiveness and safety in Crohn's disease: real‐world data from a large tertiary center;Zinger A;Clin Gastroenterol Hepatol,2023

4. DOP53 Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term Extension

5. Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial